Abstract
Abstract
Background
Wilms tumor (WT) exhibits structural and epigenetic changes at chromosome 11p15, which also cause Beckwith-Wiedemann Syndrome (BWS). Children diagnosed with BWS have increased risk for WT. The aim of this study is to identify the molecular signaling signatures in BWS driving these tumors.
Methods
We performed whole exome sequencing, methylation array analysis, and gene expression analysis on BWS-WT samples. Our data were compared to publicly available nonBWS data. We categorized WT from BWS and nonBWS patients by assessment of 11p15 methylation status and defined 5 groups– control kidney, BWS-nontumor kidney, BWS-WT, normal-11p15 nonBWS-WT, altered-11p15 nonBWS-WT.
Results
BWS-WT samples showed single nucleotide variants in BCORL1, ASXL1, ATM and AXL but absence of recurrent gene mutations associated with sporadic WT. We defined a narrow methylation range stratifying nonBWS-WT samples. BWS-WT and altered-11p15 nonBWS-WT showed enrichment of common and unique molecular signatures based on global differential methylation and gene expression analysis. CTNNB1 overexpression and broad range of interactions were seen in the BWS-WT interactome study.
Conclusion
While WT predisposition in BWS is well-established, as are 11p15 alterations in nonBWS-WT, this study focused on stratifying tumor genomics by 11p15 status. Further investigation of our findings may identify novel therapeutic targets in WT oncogenesis.
Funder
Damon Runyon Cancer Research Foundation
Publisher
Springer Science and Business Media LLC
Reference79 articles.
1. Han Q, Li K, Dong K, Xiao X, Yao W, Liu G. Clinical features, treatment, and outcomes of bilateral Wilms’ tumor: a systematic review and meta-analysis. J Pediatr Surg. 2018;53:2465–9.
2. Duffy KA, Trout KL, Gunckle JM, Krantz SM, Morris J, Kalish JM. Results from the WAGR syndrome patient registry: characterization of WAGR spectrum and recommendations for care management. Front Pediatr. 2021;9:733018.
3. Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43:705–15.
4. Hung IJ, Chang WH, Yang CP, Jaing TH, Liang DC, Lin KH, et al. Epidemiology, clinical features and treatment outcome of Wilms’ tumor in Taiwan: a report from Taiwan Pediatric Oncology Group. J Formos Med Assoc. 2004;103:104–11.
5. Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children’s oncology group study. J Clin Oncol. 2011;29:698–703.